gastrin ; Homo sapiens

13 Article(s)
Pub. Year
#Total Relationships
1 9286243 Effect of enprostil on omeprazole-induced hypergastrinemia and inhibition of gastric acid secretion in peptic ulcer patients. 1997 Aug 1
2 7875420 [Variations of plasma gastrin (basal and postprandial) in ththtreatmentof duodenal ulcer with either enprostil or ranitidine. Correlations with rates of relapse]. 1994 1
3 8038355 Effect of enprostil on serum gastrin and pepsinogen A and C levels in patients on long-term treatment with omeprazole. 1994 Apr 1
4 2121423 Effect of two-week treatment with enprostil (35 micrograms twice a day) on 24-hour serum gastrin levels. 1990 Nov 4
5 2496000 [Efficacy and tolerability of enprostil in the treatment of duodenal ulcer. Comparison with cimetidine]. 1989 1
6 2979254 Enprostil inhibits post-prandial gastrin release: a dose-response study. 1988 Aug 1
7 3061768 The significance of gastrin in the pathogenesis and therapy of peptic ulcer disease. 1988 2
8 3146539 Suppression of postprandial glucose, insulin, C-peptide, and glucose-dependent insulinotropic peptide (GIP) in man by oral administration of a prostaglandin analogue (enprostil). 1988 Oct 1
9 3111703 Enprostil reduces G-cell hyperplasia and hypergastrinemia in duodenal ulcer. 1987 1
10 3121276 Enprostil. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease. 1987 Nov 1
11 2878726 Synergistic interaction between an H2-receptor antagonist and enprostil on 24-hour intragastric pH, serum gastrin concentration, and tissue immunoperoxidase staining for gastrin, somatostatin, and serotonin in a patient with metastatic gastrinoma. 1986 1
12 3092654 Enprostil, a synthetic prostaglandin E2 analogue, inhibits meal-stimulated gastric acid secretion and gastrin release in patients with duodenal ulcer. 1986 Aug 18 1
13 3926591 Antisecretory and serum gastrin lowering effect of enprostil in patients with duodenal ulcer disease. 1985 Sep 1